TRICCAR announces results of second patient study of its Organ Fat Formula (OFF©) weight loss product

LAUGHLIN, Nev. - Feb. 4, 2019 - PRLog -- TRICCAR Holdings, Inc., aka, TRICCAR, today announced completion of its second patient study for its Organ Fat Formula. The bioceutical firm's formulation results in average weight loss of 23.2 pound in 12 weeks.

Bill Townsend, President and CEO of TRICCAR, said, "The results of our second double-blind placebo based study indicate that TRICCAR's Organ Fat Formula is proven effective at reducing excess fat while lowering food cravings. We believe this to be the first dietary supplement that consistently reduces body weight while requiring virtually no change in exercise or diet, except the exclusion of malt-based and carbonated beverages, making it the easiest way to lose weight and keep it off."

OFF utilizes several natural ingredients that performs multiple functions in the body, including:

·         Inhibiting the synthesis of fatty acids, cholesterol, triglycerides and glycogen synthesis;

·         Stimulating glycolysis (the breakdown of glucose, or sugar);

·         Stimulating glucose uptake in skeletal muscle;

·         Increasing mitochondrial creation.

"For years, researchers have sought a 'magic pill' weight loss solution," said Townsend. "As the conclusion of our second study and 2-year results of our first study indicate, our bioceutical product effectively reduces fat and appears to stabilize body weight with continued use."

One capsule of the dietary supplement is taken orally upon waking with 6 ounces of water, making it one of the easiest obesity treatments ever introduced in non-prescription form. A second capsule taken at bedtime is indicated for those considered obese.

TRICCAR is currently conducting its Series B financing and upon completion will introduce the OFF formula to the market.

TRICCAR is a Las Vegas, Nevada-based bioceutical company creating treatments that support the health of those suffering from the world's most common diseases, including, obesity, cancer, pain, diabetic neuropathy, calcium deficiency, and trigeminal neuralgia. The Company competes in markets estimated at $1 trillion in annual sales for human and animal formulations.

For additional information on TRICCAR, please visit http://www.triccar.com.